30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: RTI Surgical

Orthopaedic-related tissue distribution $28.9MM, -4%

  • Spinal $11.2MM, +15%
  • Bone Graft Substitutes/General Orthopaedic (BGS/GO) $6.0MM, -14%
  • Sports Medicine $11.6MM, -13%


  • Sports Med still facing competitive pressures; expanding lines outside of knee with products for foot, ankle, shoulder
  • Launched fenestrated Matrix HD allograft, used primarily in soft tissue repair (e.g. Achilles augmentation, tendon repair, rotator cuff, etc.); subject to CMS’ Q code, which will help with reimbursement
  • Spine supported by large stocking order from commercial distributor, plus higher overall customer demand
  • BGS/GO decline due to weak orders from large commercial distributor
  • 1st human implantation of MAPC cellular allogeneic bone graft scheduled for week of 8/5/13
  • Completed xenograft tendon 1-year evaluation of implant safety in large primate study
  • Acquired Pioneer Surgical Technology; will report revenue in categories for spine and BGS/GO, plus add Ortho Fixation in 3Q, which will comprise Pioneer’s trauma and cardiothoracic businesses